At a glance
ClinicalIndex Comparison RecordPhase 1Active· 64 enrolled
Drug / intervention
Gecacitinib Hydrochloride Tabletsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-dose, Randomized, Open-label, Four-period, Replicate Crossover, Comparative Pharmacokinetic Study of Two Formulations of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants Under Fasting Conditions.
In Brief
A Phase 1 clinical trial evaluating Gecacitinib Hydrochloride Tablets for Healthy. Active but no longer recruiting, targeting 64 participants across 1 site.
Detailed Summary
This study will compare the pharmacokinetics (PK) effect of two different formulations of Gecacitinib Hydrochloride Tablets in healthy Adult participants
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesChina
Collaborators--
Timeline
Phase 1Active
2027
First PostedMay 2026
Enrollment StartMay 2026
TodayJul 2026
Primary CompletionFeb 2027
Study CompletionMar 2027
First PostedMay 4, 2026
Enrollment StartMay 12, 2026
Primary CompletionFeb 1, 2027
Study CompletionMar 1, 2027
TodayJul 1, 2026
Enrollment to primary: 9 monthsPosted 2 months agoPrimary completion in 7 months
Interventions
Gecacitinib Hydrochloride Tabletsdrug
Administered orally